Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Neogenomics Inc (NASDAQ: NEO) closed the day trading at $7.70 up 6.06% from the previous closing price of $7.26. In other words, the price has increased by $6.06 from its previous closing price. On the day, 3.64 million shares were traded. NEO stock price reached its highest trading level at $7.86 during the session, while it also had its lowest trading level at $7.22.
Ratios:
For a better understanding of NEO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.94 and its Current Ratio is at 2.05. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.45.
On December 10, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $22.Jefferies initiated its Buy rating on December 10, 2024, with a $22 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 15 ’24 when Olivo Alicia C sold 5,175 shares for $15.36 per share. The transaction valued at 79,475 led to the insider holds 37,129 shares of the business.
ALICIA OLIVO bought 5,175 shares of NEO for $81,713 on Nov 15 ’24. On Aug 15 ’24, another insider, Olivo Alicia C, who serves as the General Counsel of the company, sold 1,040 shares for $16.05 each. As a result, the insider received 16,695 and left with 43,813 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NEO now has a Market Capitalization of 990951488 and an Enterprise Value of 1237648640. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.47 while its Price-to-Book (P/B) ratio in mrq is 1.11. Its current Enterprise Value per Revenue stands at 1.841 whereas that against EBITDA is 1883.788.
Stock Price History:
The Beta on a monthly basis for NEO is 1.61, which has changed by -0.5035461 over the last 52 weeks, in comparison to a change of 0.09765589 over the same period for the S&P500. Over the past 52 weeks, NEO has reached a high of $19.11, while it has fallen to a 52-week low of $6.08. The 50-Day Moving Average of the stock is -19.18%, while the 200-Day Moving Average is calculated to be -44.91%.
Shares Statistics:
Over the past 3-months, NEO traded about 1.92M shares per day on average, while over the past 10 days, NEO traded about 4243580 shares per day. A total of 128.36M shares are outstanding, with a floating share count of 127.16M. Insiders hold about 1.20% of the company’s shares, while institutions hold 98.45% stake in the company. Shares short for NEO as of 1744675200 were 4979102 with a Short Ratio of 2.59, compared to 1741910400 on 4224233. Therefore, it implies a Short% of Shares Outstanding of 4979102 and a Short% of Float of 5.3600002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Neogenomics Inc (NEO) is the result of assessments by 13.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.05, with high estimates of $0.08 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.22 and $0.11 for the fiscal current year, implying an average EPS of $0.16. EPS for the following year is $0.31, with 13.0 analysts recommending between $0.4 and $0.21.
Revenue Estimates
13 analysts predict $182.96M in revenue for the current quarter. It ranges from a high estimate of $189.26M to a low estimate of $179.8M. As of the current estimate, Neogenomics Inc’s year-ago sales were $164.5MFor the next quarter, 13 analysts are estimating revenue of $191.89M. There is a high estimate of $197M for the next quarter, whereas the lowest estimate is $186.55M.
A total of 14 analysts have provided revenue estimates for NEO’s current fiscal year. The highest revenue estimate was $753.02M, while the lowest revenue estimate was $731.58M, resulting in an average revenue estimate of $743.73M. In the same quarter a year ago, actual revenue was $660.57MBased on 14 analysts’ estimates, the company’s revenue will be $827.68M in the next fiscal year. The high estimate is $840M and the low estimate is $814.35M.
